Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 23 for “"Remicade"”.
-
High dose interval vitamin D supplementation in pediatric patients with inflammatory bowel disease receiving Remicade
… with IBD. We chose to study patients receiving Remicade, an immunosuppressive monoclonal antibody therapy administered intravenously, as the need for scheduled hospital-based infusions provides a unique opportunity to ensure compliance in our study population. METHODS: We identified consecutive …
-
Serial changes in serum and fecal biomarkers levels in pediatric patients with IBD treated with remicade
… Children’s Hospital. All patients were naïve to Remicade at the time of enrollment. The objective of the study was to collect baseline stool and serum samples during their first Remicade infusion as well as at all follow up infusions. Serum samples were analyzed for C-reactive protein (CRP), …
-
Implementation of high dose interval vitamin D supplementation in pediatric patients with inflammatory bowel disease receiving remicade
… in pediatric patients with IBD treated with Remicade. A secondary aim is to study the association between changes in serum 25OHD (25-hydroxyvitamin D3) levels and clinical and biochemical markers of IBD. The findings from this study will provide preliminary data for future studies using …
-
Effects of Resistance Training on Insulin Sensitivity and Markers of Inflammation in Rheumatoid Arthritis Patients Treated with Remicade
INTRODUCTION Rheumatoid arthritis (RA) is a disease of chronic inflammation in the joints and organs. RA patients exhibit 4-fold increased incidence of CVD, increased prevalence of insulin resistance (IR) and increased mortality. Aerobic and resistance training (RT) programs have been suggested for …
-
Serial fecal biomarker measurements predict response to biologic therapy in children with IBD
… treated with the anti-TNF therapy, infliximab (Remicade). To accomplish this, we will assess the changes in serum and fecal biomarker levels over the course of treatment and correlate the changes in fecal and serum biomarker levels with clinical, biochemical, and endoscopic outcome variables. …
-
Valoración de la eficacia de Infliximab biosimilar (CT-P13, remsima®) frente al Infliiximab original (Remicade®) en pacientes con enfermedad inflamatoria intestinal.
… en remisión en tratamiento Infliximab original (Remicade®) frente a Infliximab biosimilar (CT-P13) durante 12 meses, así como los eventos adversos y los costes de los tratamientos. Material y métodos: se ha realizado un estudio observacional comparativo de dos cohortes y un estudio antes-después …
-
Serum and fecal biomarkers predict response to Infliximab therapy in pediatric patients with inflammatory bowel disease
… treated with the anti-TNF therapy Infliximab (Remicade). The second objective is to study the relationship between changes in these biomarker levels and the clinical, biochemical, and endoscopic outcome parameters of IBD in patients. This is a multicenter, longitudinal, cohort study following …
-
Interval high-dosage vitamin D therapy in patients with inflammatory bowel disease
… study this hypothesis in patients treated with Remicade (infliximab), which necessitates regular (monthly or bimonthly) office visits. Patients are eligible if they are being treated with Remicade, have a documented 25-hydroxyvitamin D less than 30.0ng/mL within 8 weeks of enrollment, and do not …
-
The Effects of a 16-week Individualized, Intensive Strength Training Program for Patients with Rheumatoid Arthritis
… in rheumatoid arthritis (RA) patients taking Remicade™ (Infliximab) would improve strength, body composition, disease activity, physical function, pain and quality of life outcomes , as compared to RA patients on Remicade™ with no strength training program. Methods. Twenty-four patients with …
-
Therapie der Spondylitis ankylosans mit dem monoklonalen chimären anti-TNF-Antikörper Infliximab (Remicade®):Klinische Wirksamkeit und Einfluss auf die HLA-Oberflächenexpression auf Lymphozyten mit besonderer Berücksichtigung von HLA-B27
In der vorliegenden Arbeit wurden therapeutische und immunmodulatorische Effekte einer TNF-Blockade bei Patienten mit aktiver Spondylitis ankylosans untersucht. Hierzu wurde an 10 Patienten während einer 60wöchigen Infliximabtherapie eine Evaluation von Therapiewirksamkeit und -sicherheit, sowie …
-
Development of holistic analytical methods for disease biomarker discovery and the study of drug efficasy in autoimmune disease
… starting from 6 up to 11 weeks of mouse age. Remicade treatment of TG animals found beneficial in progressive swift of the metabolic phenotype from TG to WT like one. Strong evidence of phenotypic differentiation with steroid related marker was found. On the other hand targeted metabolic …
-
Pharmacological Inhibition of TAK1 as a Therapeutic Target to Reduce Inflammation and Pain
… in those with greater pain. TNF antibodies (eg, Remicade, Humira and Cimzia) are currently available for the treatment of inflammatory pain conditions such as rheumatoid arthritis. However, 40% of patients fail to respond to TNF antibodies, leading for the need to develop novel small molecule TNF …
-
Construction of synthetic antibodies against tumour necrosis factor alpha
… monoclonal antibody (mAb) infliximab (Remicade®) by means of construction of medium-sized antibody mimics, denoted as synthetic antibodies. The synthetic antibodies constructed by Cu(I) catalyzed azide-alkyne cycloaddition of complementarity determining region (CDR) mimics onto …
-
The role of the innate immune system in microbially induced intestinal inflammation and neoplasia
… pharmaceutical therapies such as infliximab (Remicade[registered trademark]) carry several side effects and are not efficacious in all patients. Thus, more selective treatments are needed. One necessary step in the development of such agents is a more precise understanding of which cells in …
-
Strengths, weaknesses, and opportunities: three tales demonstrating the use, usefulness, and limitations of Canadian post-market data of adverse drug reactions in real-world settings
… outcomes associated with two brand-name drugs, Remicade and Humira. This project highlights that randomized controlled trials may not accurately reflect the true incidence of certain ADR outcomes in the real-world. Regarding weaknesses, Dissertation Project 2 demonstrates that the CVAR database …
-
Kontrollierte Einführung des Infliximab-Biosimilars CT-P13 bei Patienten mit Morbus Crohn und Colitis ulcerosa in einer großen deutschen Zentrumskohorte
… kontrollierte und verblindete Umstellung von Remicade auf CT-P13 anboten und die Daten retrospektiv analysierten. Primärer Endpunkt war eine Kombination aus dem Erreichen einer klinischen Remission nach 52 Wochen mit Toleranz der Studienmedikation bis zum Ende. Remissionsraten wurden in Wochen …
-
Monoclonal Antibody Expression and Novel Purification in Nicotiana benthamiana
… Rituxan (rituximab), Humira (adalimumab) and Remicade (infliximab), which are cornerstones in this type of sector. With the cost of development to market approval rising astronomically for a new drug, new ways to produce and process these molecules becomes a paramount objective to ultimately …
-
Coste-efectividad de la consulta enfermera de práctica avanzada en el manejo del paciente con artritis reumatoide en hospital de día
… reumatoide (AR) en tratamiento con Infliximab (Remicade©) gestionado por una enfermera especializada en reumatología, así como analizar la evolución de los pacientes atendidos desde el año 2000 hasta el año 2015. Pacientes y método. Pacientes: pacientes con diagnóstico de AR según los criterios …
-
The Effectiveness of Leflunomide Etanercept and Infliximab in the Treatment of Rheumatoid Arthritis:a systematic review
… such as etanercept (Enbrel®) and infliximab (Remicade®), and leflunomide (Arava®) that targets proliferating T-cells offer a novel approach. With the approval of marketing these drugs by the Food and Drug Administration (FDA), the safety and efficacy data for these new disease modifying …
Page 1 of 2